Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

Theo De Witte; Luca Malcovati; Pierre Fenaux; David Bowen; Argiris Symeonidis; Moshe Mittelman; Reinhard Stauder; Guillermo Sanz; Jaroslav Čermák; Saskia Langemeijer; Eva Hellström-Lindberg; Ulrich Germing; Mette Skov Holm; Krzysztof Mądry; Aurelia Tatic; António Medina Almeida; Aleksandar Savic; Inga Mandac Rogulj; Raphael Itzykson; Marlijn Hoeks; Hege Gravdahl Garelius; Dominic Culligan; Ioannis Kotsianidis; Lionel Ades; Arjan A Van de Loosdrecht; Corine Van Marrewijk; Ge Yu; Simon Crouch; Alex Smith

doi:10.3324/haematol.2020.266817

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

Haematologica. 2020 Nov 1;105(11):2516-2523. doi: 10.3324/haematol.2020.266817.

Authors

Theo De Witte¹, Luca Malcovati², Pierre Fenaux³, David Bowen⁴, Argiris Symeonidis⁵, Moshe Mittelman⁶, Reinhard Stauder⁷, Guillermo Sanz⁸, Jaroslav Čermák⁹, Saskia Langemeijer¹⁰, Eva Hellström-Lindberg¹¹, Ulrich Germing¹², Mette Skov Holm¹³, Krzysztof Mądry¹⁴, Aurelia Tatic¹⁵, António Medina Almeida¹⁶, Aleksandar Savic¹⁷, Inga Mandac Rogulj¹⁸, Raphael Itzykson³, Marlijn Hoeks¹⁰, Hege Gravdahl Garelius¹⁹, Dominic Culligan²⁰, Ioannis Kotsianidis²¹, Lionel Ades³, Arjan A Van de Loosdrecht²², Corine Van Marrewijk¹⁰, Ge Yu²³, Simon Crouch²³, Alex Smith²³

Affiliations

¹ Department of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen; TdW and LM both contributed equally as co-first authors. theo.dewitte@radboudumc.nl.
² Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia; TdW and LM both contributed equally as co-first authors. theo.dewitte@radboudumc.nl.
³ Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris. theo.dewitte@radboudumc.nl.
⁴ St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds. theo.dewitte@radboudumc.nl.
⁵ Department of Medicine, Division of Hematology, University of Patras Medical School, Patras. theo.dewitte@radboudumc.nl.
⁶ Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv. theo.dewitte@radboudumc.nl.
⁷ Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck. theo.dewitte@radboudumc.nl.
⁸ Department of Haematology, Hospital Universitario y Politécnico La Fe, Valencia, and CIBERONC, Madrid. theo.dewitte@radboudumc.nl.
⁹ Department of Clinical Hematology, Inst. of Hematology and Blood Transfusion, Praha. theo.dewitte@radboudumc.nl.
¹⁰ Department of Hematology, Radboud University Medical Center, Nijmegen. theo.dewitte@radboudumc.nl.
¹¹ Department of Medicine, Division Hematology, Karolinska Institutet, Stockholm. theo.dewitte@radboudumc.nl.
¹² Department of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf. theo.dewitte@radboudumc.nl.
¹³ Department of Haematology, Aarhus University Hospital, Aarhus. theo.dewitte@radboudumc.nl.
¹⁴ Department of Haematology, Oncology and Internal Medicine, Warszawa Medical University, Warszawa. theo.dewitte@radboudumc.nl.
¹⁵ Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest. theo.dewitte@radboudumc.nl.
¹⁶ Department of Clinical Hematology, Hospital da Luz, Lisbon. theo.dewitte@radboudumc.nl.
¹⁷ Clinic of Hematology - Clinical Center of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad. theo.dewitte@radboudumc.nl.
¹⁸ Department of Internal Medicine, Division of Hematology, Merkur University Hospital, Zagreb. theo.dewitte@radboudumc.nl.
¹⁹ Department of Specialist Medicine, Sahlgrenska University Hospital, Göteborg. theo.dewitte@radboudumc.nl.
²⁰ Department of Haematology, Aberdeen Royal Infirmary, Aberdeen. theo.dewitte@radboudumc.nl.
²¹ Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis. theo.dewitte@radboudumc.nl.
²² Department of Hematology - Cancer Center Amsterdam, Amsterdam UMC, Location VU University Medical Center, Amsterdam. theo.dewitte@radboudumc.nl.
²³ Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York. theo.dewitte@radboudumc.nl.

No abstract available

MeSH terms

Humans
Myelodysplastic Syndromes* / diagnosis
Myelodysplastic Syndromes* / epidemiology
Myelodysplastic Syndromes* / therapy
Registries

Grants and funding

Funding The work of the EUMDS Registry is supported by an educational grant from Novartis Pharmacy B.V. Oncology Europe, Amgen Limited, and Celgene. This work is part of the MDSRIGHT activities, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement n. 634789 - “Providing the right care to the right patient with MyeloDysplastic Syndrome at the right time”. The Pavia Registry is supported by a grant from Associazione Italiana per la Ricerca sul Cancro (IG 20125). Part of the work is supported by Translational Implementation of genetic evidence in the management of MDS (TRIAGE-MDS) (TRIAGE-MDS, Austrian Science Found I 1576) within the TRANSCAN - Primary and secondary prevention of cancer call (ERA Net).